• Retinoblastoma is a severe eye cancer of infancy and childhood and can cause blindness or even death.
• Currently, the invasive intravitreal drug administration used in clinics is unpleasant for patients and can lead to side effects such as ocular haemorrhage, endophthalmitis and retinal detachment, etc.
• Thus, effective drug administration routes in a less invasive manner are desirable for the treatment of retinoblastoma.

Underlying Mechanism

• Three-legged small molecules are the main building blocks of the nanocarriers.
• The cleavage of the three-legged molecules upon light irradiation can quickly lead to the breakdown of the nanocarriers, resulting in the rapid release of the drugs only at the irradiated sites.

Benefits

• On-demand drug delivery to achieve a less invasive and more efficient treatment
• Metal free
• Platform technology for delivering different drugs

Target drug delivery system for eye or skin diseases

Patents

• PCT Application No. PCT/CN2021/081262

IP Status

• Patent application submitted